LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.87 -2.27

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.81

Max

4.11

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-12M -27M
Pardavimai	-5.3M 663K
P/E Sektoriaus vid.	22.5 49.8
Pelno marža	-3,998.492
Darbuotojai	69
EBITDA	-13M -27M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+226.63% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-234M 910M
Ankstesnė atidarymo kaina	6.14
Ankstesnė uždarymo kaina	3.87

Naujienos nuotaikos

By Acuity

60%

40%

262 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

0.7658 / N/A Palaikymas ir pasipriešinimas

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-11 22:15; UTC

Įsigijimai, susijungimai, perėmimai

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026-05-11 23:46; UTC

Rinkos pokalbiai

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026-05-11 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026-05-11 23:33; UTC

Rinkos pokalbiai

Gold Rises on Possible Position Adjustments -- Market Talk

2026-05-11 22:37; UTC

Rinkos pokalbiai

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026-05-11 22:32; UTC

Uždarbis

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026-05-11 22:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026-05-11 21:49; UTC

Uždarbis

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026-05-11 21:42; UTC

Rinkos pokalbiai

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026-05-11 21:31; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026-05-11 21:23; UTC

Įsigijimai, susijungimai, perėmimai

CSG Systems Sale to NEC Gets CFIUS Clearance

2026-05-11 21:12; UTC

Uždarbis

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026-05-11 21:12; UTC

Uždarbis

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026-05-11 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-11 20:44; UTC

Uždarbis

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026-05-11 20:43; UTC

Uždarbis

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Rev $136.4M >CLSK

2026-05-11 20:30; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Cont Ops EPS $2.24 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Rev $1.6B >STE

2026-05-11 20:30; UTC

Uždarbis

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Adj EPS $2.83 >STE

2026-05-11 20:22; UTC

Karštos akcijos

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026-05-11 19:37; UTC

Uždarbis

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026-05-11 19:32; UTC

Rinkos pokalbiai

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

226.63% į viršų

12 mėnesių prognozė

Vidutinis 13 USD 226.63%

Aukščiausias 16 USD

Žemiausias 11 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

262 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.